Full Press Release Details
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034)
PRIMA BIOMED TO PRESENT AT THE 16TH ANNUAL BIO CEO & INVESTOR CONFERENCE
SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ:
PBMD; ISIN: US74154B2034) ( Prima , the Company ) has announced today that Matthew Lehman, its Chief Executive Officer, will present at the 16th Annual BIO CEO & Investor Conference on Monday, 10 February 2014 in New York
City at the Waldorf Astoria Hotel. Mr. Lehman will provide an overview of the Company and its corporate activities and will be available to participate in one-on-one meetings.
The Company s presentation is scheduled to begin at 10:30am Eastern US Time and will be available via a live audio webcast. To access the webcast, please
go to http://www.veracast.com/webcasts/bio/ceoinvestor2014/93126297249.cfm. A replay of the webcast will be available for 90 days following the presentation and may be accessed by visiting Prima BioMed s website.
Prima BioMed is a globally active leader in the development of personalized immunocellular therapeutic products for the treatment of cancer. Prima is dedicated
to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Prima s lead product is CVac , an
autologous dendritic cell-based product currently in clinical trials. www.primabiomed.com.au
For further information please contact:
Ms. Jessica Brown, Prima BioMed Ltd.
+1 (919) 710-9061; jessica.brown@primabiomed.com.au
Australia Investor/Media:
+61 (0) 420 991 574; james@mandatecorporate.com.au
Europe Investor/Media:
Mr. Axel M hlhaus, edicto
+49 (0) 69 905505-52; amuehlhaus@edicto.de
Prima BioMed Ltd, Level 7, 151 Macquarie Street, Sydney NSW 2000
Phone: +61 2 9276 1224 Fax: +61 2 9276 1284
www.primabiomed.com.au ABN 90 009 237 889